Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biohaven Pharmaceutical Holding Company Ltd (BHVN)

Biohaven Pharmaceutical Holding Company Ltd (BHVN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,955,253
  • Shares Outstanding, K 52,154
  • Annual Sales, $ 0 K
  • Annual Income, $ -240,920 K
  • 60-Month Beta 0.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -2.03
  • Number of Estimates 5
  • High Estimate -1.40
  • Low Estimate -3.35
  • Prior Year -1.53
  • Growth Rate Est. (year over year) -32.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.94 +6.17%
on 08/15/19
45.84 -14.44%
on 07/17/19
-6.08 (-13.42%)
since 07/16/19
3-Month
36.94 +6.17%
on 08/15/19
67.86 -42.20%
on 06/07/19
-24.56 (-38.51%)
since 05/16/19
52-Week
29.17 +34.45%
on 12/24/18
67.86 -42.20%
on 06/07/19
+4.12 (+11.74%)
since 08/16/18

Most Recent Stories

More News
Biohaven Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Business Developments

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN, the "Company"), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological...

BHVN : 39.22 (+4.61%)
Biohaven Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Business Developments

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN, the "Company"), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological...

BHVN : 39.22 (+4.61%)
Biohaven Completes Enrollment In Pivotal Phase 3 Migraine Prevention Trial

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases today...

BHVN : 39.22 (+4.61%)
Biohaven Enrolls First Patient In Phase 3 Clinical Trial Of Verdiperstat, Oral Myeloperoxidase Inhibitor, For The Treatment Of Multiple System Atrophy

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company"), a clinical stage biopharmaceutical company with a portfolio of late-stage product candidates for neurological and...

BHVN : 39.22 (+4.61%)
Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric...

BHVN : 39.22 (+4.61%)
Biohaven's Nurtec (riluzole) 505(b)2 Application for Amyotrophic Lateral Sclerosis Affected by Issues Related to Apotex Plant: Complete Response Letter (CRL) Received From FDA Related to Isolated Drug Substance Supply Used in Bioequivalence Study

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric...

BHVN : 39.22 (+4.61%)
Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announces that The Lancet published online positive results from a Phase 3 pivotal clinical trial of rimegepant Zydis® orally dissolving tablet...

BHVN : 39.22 (+4.61%)
Biohaven Launches 'Demand More' Campaign At 2019 American Headache Society Annual Scientific Meeting: Highlighting Patient Needs In Acute Treatment Of Migraine

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), has launched a campaign called 'Demand More' highlighting what patients want and need from an acute treatment of migraine in their own words....

BHVN : 39.22 (+4.61%)
Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term Safety

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced it will present 16 scientific presentations (oral and poster) highlighting new efficacy and safety data for rimegepant from Biohaven's...

BHVN : 39.22 (+4.61%)
Biohaven's Rimegepant Positive Phase 3 Trial For Acute Treatment Of Migraine Published In The New England Journal of Medicine

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), announced today that positive results from a Phase 3 pivotal clinical trial of rimegepant, Biohaven's small molecule calcitonin gene-related peptide...

BHVN : 39.22 (+4.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade BHVN with:

Business Summary

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which...

See More

Key Turning Points

2nd Resistance Point 40.75
1st Resistance Point 39.98
Last Price 39.22
1st Support Level 37.84
2nd Support Level 36.47

See More

52-Week High 67.86
Fibonacci 61.8% 53.08
Fibonacci 50% 48.51
Fibonacci 38.2% 43.95
Last Price 39.22
52-Week Low 29.17

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar